

# RSC Advances



This is an *Accepted Manuscript*, which has been through the Royal Society of Chemistry peer review process and has been accepted for publication.

*Accepted Manuscripts* are published online shortly after acceptance, before technical editing, formatting and proof reading. Using this free service, authors can make their results available to the community, in citable form, before we publish the edited article. This *Accepted Manuscript* will be replaced by the edited, formatted and paginated article as soon as this is available.

You can find more information about *Accepted Manuscripts* in the [Information for Authors](#).

Please note that technical editing may introduce minor changes to the text and/or graphics, which may alter content. The journal's standard [Terms & Conditions](#) and the [Ethical guidelines](#) still apply. In no event shall the Royal Society of Chemistry be held responsible for any errors or omissions in this *Accepted Manuscript* or any consequences arising from the use of any information it contains.

1           **Preparation, characterization and application of Antibody-**  
2           **Conjugated Magnetic Nanoparticles in the Purification of**  
3           **Begomovirus**

4   **Michael Immanuel Jesse<sup>a</sup>, R. Sukanya<sup>b</sup>, D.Nallusamy<sup>a</sup>, T.Raja**  
5   **Muthuramalingam<sup>a</sup>, S.U.Mohammed Riyaz<sup>a</sup>, G.Dharanivasan<sup>a</sup>, K.Kathiravan<sup>\*a</sup>**

6   <sup>a</sup>Department of Biotechnology, University of Madras, Guindy, Chennai – 600 025,  
7   Tamil Nadu, India.

8   <sup>b</sup>Department of Bioscience & Biotechnology, Banasthali University, Rajasthan –  
9   304022, India.

10

11   \*Corresponding author

12   email: drkkathiravan@gmail.com. Tel : +91 44 2220 2744

13

14   **Keywords**

15   Begomovirus, Magnetic nanoparticles, Antibody, Bio-separation, Electrophoresis.

16

17

18

19

20

21

22

23

24

25 **ABSTRACT**

26 Begomovirus (family-*Geminiviridae*) infect a wide range of commercial crops like  
27 tomato, bean, cassava, cotton, cucurbits and chilli. Purification of begomoviruses  
28 from the infected plants, in particular from vegetable crops remains challenging. The  
29 conventional process of begomovirus purification requires sophisticated instruments  
30 and moreover, it is time-consuming. Herein, we used antibody-conjugated magnetic  
31 nanoparticles (Ab-MNPs) to purify begomoviruses from the infected plants. MNPs  
32 were prepared using the co-precipitation method (at pH between 8-12 & size 25nm).  
33 The prepared MNPs were functionalized with APTES (at pH 7) and confirmed with  
34 FTIR. Thus functionalized MNPs were conjugated with polyclonal antibodies (pAbs)  
35 using the EDC-NHS chemistry (size = 80nm). The crude extract prepared from the  
36 infected plants were suspended in the solution of Ab-MNPs and separated using a  
37 magnet. The captured virus particles were released into the aqueous solution (at pH  
38 10). SDS-PAGE analysis and PCR analysis were done to confirm the presence of viral  
39 infection.

40

## 41 Introduction

42 Researchers show great interest from the wide range of applications of magnetic  
43 nanoparticles (MNPs) in the following disciplines including magnetic fluids,<sup>1</sup>  
44 catalysis,<sup>2,3</sup> biotechnology/biomedicine,<sup>4</sup> magnetic resonance imaging,<sup>5,6</sup> data storage<sup>7</sup>  
45 and environmental remediation.<sup>8,9</sup> The successful application of magnetic  
46 nanoparticles in various areas of research is highly determined by their stability. The  
47 common methods for the synthesis of magnetic nanoparticles include co-precipitation,  
48 Thermal decomposition, hydrothermal synthesis, micro-emulsion, sonochemical  
49 synthesis<sup>10</sup> and other methods involved are electrochemical synthesis,<sup>11</sup> laser  
50 pyrolysis technique<sup>12</sup> and microorganism/bacterial synthesis.<sup>13</sup> Among these  
51 techniques, co-precipitation is considered to be facile and efficient way to synthesize  
52 MNPs. Based on the reaction between the ferric and ferrous ions at the molar ratio of  
53 1:2 combined with high pH, ionic strength and nitrogen bubbling contributes to the  
54 decrease in the size of the nanoparticles.<sup>14,15</sup> The Fe<sub>3</sub>O<sub>4</sub> is expected to be synthesized  
55 between pH 8 to 14.<sup>15</sup> Further, dispersion of MNPs could be achieved through  
56 different strategies of bio-functionalization. The magnetic nanoparticles that are  
57 below 100 nm diameter possess a large surface area, lower sedimentation rates and  
58 improved tissular diffusion<sup>16,17,18</sup> and the dipole-dipole interactions are significantly  
59 reduced due to their nm scale is another advantage<sup>19</sup>. It is due to their small size and  
60 high surface area, magnetic nanoparticles have distinct characteristics of their  
61 application in bioseparation compared to the conventional commercially available  
62 microbeads. The characteristics such as their good dispersibility, rapid and efficient  
63 binding of biomolecules and reversible/controllable flocculation.<sup>20</sup>

64 The deep understanding and knowledge on the bio-functionalizing moieties and their  
65 interstellar distribution on the nanoparticle surfaces favors the functionalization of  
66 biomolecules. Bare MNPs possess certain limitations that it is unstable in strong  
67 acidic solution and tend to undergo leaching thereby reducing its reusability and  
68 lifetime. In the absence of appropriate functional groups, the hydrophobic surfaces on  
69 bare MNPs tend them to form agglomeration. Such limitations would make these  
70 MNPs unsuitable for immobilization of proteins and peptides. Therefore, functional  
71 groups including silanes, carboxylates and diols have been known to demonstrate  
72 surface modification strategies of metal nanoparticles like magnetite and  
73 maghemite.<sup>21</sup> Various surface modification strategies have been developed to

74 renovate the hydrophobic iron oxide nanoparticles to hydrophilic particles using  
75 biocompatible coating materials, biomolecules and hydrophilic small molecules.<sup>22</sup>  
76 Several surfactants including oleic acid, lauric acid, alkylsulphonic acids, and  
77 alkylphosphonic acids have been used.<sup>23</sup> Polyethylene glycol (PEG),  
78 polyvinylpyrrolidone (PVP), poly(ethylene-co-vinyl acetate), poly(lactic-co-glycolic  
79 acid) (PLGA), and polyvinyl alcohol (PVA) are the polymers that have been used.<sup>24</sup>  
80 Natural dispersants including gelatin, dextran, polylactic acids, starch, albumin,  
81 liposomes, chitosan, ethyl cellulose have also been extensively employed for coating  
82 purpose in aqueous medium. Silanization is the most widely used technique to  
83 functionally modify the surface of bare magnetic nanoparticles due to its  
84 characteristics such as satisfying responsivity, low cytotoxicity, high stability under  
85 acidic conditions, inertness to redox reactions and easy to perform surface chemical  
86 modification. Their ability to react in either aqueous media or organic solvents at  
87 moderate temperatures under moderate conditions makes the silanization strategy  
88 ideal for surface functionalization.

89 The silane molecules are activated by the process of hydrolysis following which  
90 condensation occurs between Si-OH groups of the silanol and the hydroxyl groups on  
91 the MNP surface forming stable bonds on the surface.<sup>25</sup> The bio-functionalized  
92 magnetic nanoparticles have enormous interest due to their wide use in the field of  
93 biotechnology and bio-nanomedicine.<sup>26,27</sup> Bio-functionalized magnetic nanoparticles  
94 have been aided in the immobilization of biological materials including low molecular  
95 weight ligands, peptides, proteins, polysaccharides, polyunsaturated fatty acids, DNA,  
96 plasmids, siRNA etc.<sup>28</sup> The conjugation of antibody to nanoparticles make them  
97 'super-recognizers' that could specifically target antigen of interest.<sup>29</sup>

98 The wide applications of antibody-conjugated magnetic nanoparticles include  
99 therapeutics, diagnostics and bio-separation. Antibody-conjugated magnetic  
100 nanoparticles (Ab-MNPs) are widely used in [1] targeting and treatment of various  
101 cancers,<sup>30,31</sup> [2] magnetic resonance and imaging,<sup>32,33</sup> [3] Hyperthermia<sup>34</sup> and [4]  
102 magnetic separation, purification and immunoassay.<sup>35</sup> Magnetic bio-separation is the  
103 recently developing area in the field of nano-biotechnology which could slowly  
104 deteriorate the use of sophisticated, expensive instruments such as ultra-centrifuges  
105 used for separation. The applications of magnetic nanoparticles in the bio-separation  
106 techniques can solve different problems including high-cost and process

107 complexation.<sup>36,37,38</sup> The significant ability of bio-moiety (antibody) functionalized iron  
108 oxide nanoparticles in bio-separation will gain greater interests of industrial  
109 community in the separation of target molecules. Magnetic bio-separation possesses  
110 certain advantages such as 1) their ability to recover small particles (0.05 - 1 $\mu$ m) in  
111 the presence of multi-components or biological debris,<sup>39</sup> 2) efficiently applicable for  
112 large-scale purification, 3) allows to save more time and money,<sup>38</sup> 4) centrifugation  
113 steps can be avoided and 5) cross-contamination could be avoided. The antibody-  
114 conjugated iron oxide nanoparticles have been employed in the separation of cancer  
115 cells,<sup>39</sup> pathogens including *E.coli* and *Staphylococcus*<sup>42</sup> and CD3+ T-cells,<sup>43</sup> in  
116 addition, magnetic separation and immunoassay on multi-antigen system<sup>44</sup> have been  
117 demonstrated. Some of the major advantages of employing nanoparticles as platform  
118 for functionalization of biomolecules are 1) their small size, 2) High surface area, 3)  
119 Modification using functional groups increasing its high capacity or selectivity and  
120 greater stability during storage.

121 In this study, we have demonstrated the magnetic bio-separation of Begomovirus  
122 from the infected plant samples. Begomovirus is considered to be a largest and most  
123 vital genus that belongs to the family *Geminiviridae*. These viruses tend to infect  
124 mostly dicotyledonous plants. These damaging plant viruses show severe threat to  
125 global food security. The symptoms of virus infection in plants are leaf curling,  
126 mosaic, vein yellowing and stunting of plant growth.<sup>45,46,47</sup> These viruses are  
127 transmitted by white-flies (*Bemisia tabaci*). These are single-stranded DNA viruses  
128 that possess icosahedral twinned geminate particles. The transmission of these viruses  
129 by insects are mostly dependent on the coat protein that are adapted to different  
130 receptors of insects.<sup>45</sup> In 1998, Swanson et al. has made the epitope profiles and  
131 antigenic properties of Begomovirus coat protein within genus. Swanson et al (1988)  
132 used both monoclonal antibodies and polyclonal antibodies for epitope profiling on  
133 the coat protein of Begomovirus.<sup>48</sup>

134 Here in, we have conjugated the polyclonal antibodies (pAbs) specific to the genus  
135 Begomovirus on the surface of iron oxide nanoparticles for its bio-separation from the  
136 symptom showing squash plants *Benincasa hispida* for which we have reported the  
137 incidence of *Squash Leaf Curl China virus* (SLCCNV), a species of begomovirus.<sup>49</sup>  
138 So far, conventional methodologies like ultra-centrifugation that are very expensive  
139 and time-consuming, have been used for the separation and purification of

140 Begomovirus from the debris.<sup>50</sup> We demonstrate a low-cost, time saving purification  
141 technique that employs antibody-conjugated magnetic nanoparticles in the  
142 purification of begomovirus from the infected plant. This technique of employing iron  
143 oxide nanoparticles for the separation/purification of begomovirus from the infected  
144 ash gourd (*Benincasa hispida*) plant samples would skip the centrifugation process  
145 with the great power of magnets.

146

## 147 **Material and Methods**

### 148 **Materials**

149 All reagents used for the synthesis of iron oxide nanoparticles were analytical grade  
150 purchased commercially and used as received. Ferrous chloride hydrated extra pure  
151 (code no. 03846) and Ferric chloride anhydrous 98% extra pure (code no. 03817)  
152 were obtained from Loba Chemie Pvt. Ltd. Sodium Hydroxide pellets were obtained  
153 from RANKEM (code no. S0270). Sodium hydrogen phosphate –monobasic  
154 (1949146) and dibasic (1949144), Sodium lauryl sulphate (1948101), Tris buffer  
155 (2049171), Acrylamide, Bis-acrylamide, TEMED and APS were purchased from  
156 Sisco Research Laboratories Pvt. Ltd. APTES (154766) was obtained from MP  
157 biomedical. Hydrochloric acid was purchased from Merck and nitric acid from  
158 Fisher Scientific India Pvt. Ltd. Ultrapure Milli-Q water was used throughout the  
159 study (Millipore). Aqua regia was freshly prepared for washing glasswares used for  
160 the synthesis of iron oxide nanoparticles.


161

### 162 **In situ precipitation of iron oxide nanoparticles modified with APTES**

163 Magnetic nanoparticles were synthesized with modifications on the previously  
164 demonstrated protocols<sup>51-57</sup> through co-precipitation of ferrous and ferric salts under  
165 the presence of N<sub>2</sub> gas with the help of NaOH solution. 16.25g of FeCl<sub>3</sub> and 6.35g of  
166 FeCl<sub>2</sub> were dissolved in 200 ml of distilled water, which leads to Fe<sup>2+</sup>/Fe<sup>3+</sup> ratio of 2:1  
167 in the solution. The nitrogen gas provides an inert atmosphere, thereby preventing the  
168 oxidative conversion of magnetite to maghemite particles. The solution was stirred for  
169 1 h at 30°C. The co-precipitation reaction has taken place by raising the pH of the

170 solution to 12 by adding 2M NaOH drop-wise into the reaction system at 70°C. The  
171 reaction was sustained for 3 hours at 70°C with the continuous supply of nitrogen gas.

172 The following reaction occurs during the synthesis process.



174 After the completion of the reaction, the synthesized particles were cooled down and  
175 washed with double deionized water. The particles were repeatedly washed with the  
176 deionized water to remove excess of NaOH which was done till the pH reaches 6-7.  
177 According to Laconte et al (2005), the as-of synthesized magnetic nanoparticles  
178 aggregated due to the van der Waals forces resulting in the increase in the size of the  
179 particles<sup>16</sup>. The black precipitate was sonicated for separating the particles for further  
180 modification. The particles were surface modified with the silanization process. 80 ml  
181 of 10% APTES was added drop-wise to ferro-fluid suspension under constant stirring.  
182 Before addition, the pH of the APTES solution was adjusted to 4 using glacial acetic  
183 acid. The reaction content was vigorously stirred for 1 h in nitrogen atmosphere. The  
184 particles were thoroughly washed with double deionized water through continuous  
185 collection and dispersion process (magnetic decantation) until the solution reached  
186 neutral pH. A small amount of precipitate was dried in a vacuum desiccator.

187

### 188 **Conjugation of Antibodies to the APTES-MNPs**

189 The antibody was conjugated on the magnetic nanoparticles based on the following  
190 protocol. The antibody was conjugated to the magnetic nanoparticles in 1:200  
191 dilution. 10mM EDC and 5mM NHS were prepared in 0.1 M MES buffer at pH 5  
192 and incubated with anti-ACMV antibody in a humid chamber for 1 h. Then 20µl of  
193 EDC-NHS activated antibody solution was added to MNP solution. Following which  
194 20µl of 10mM phosphate buffer was added to 980µl of reaction solution. The reaction  
195 mixture was incubated for overnight at 30°C in vortex mixer. Antibody-conjugated  
196 MNPs were separated by placing the tube in a magnet. The pellet was collected and  
197 re-suspended in PBS for washing. Totally three washing steps were done and finally  
198 suspended in PBS.

199

200 **Field survey and collection of squash plants showing begomovirus-infection**  
201 **symptoms**

202 The squash plants *Benincasa hispida* showing symptoms of begomovirus infection  
203 was collected. Upon begomovirus infection, the plants develop symptoms including  
204 leaf curling, mosaic, vein yellowing or stunting of plant growth. The plant leaf  
205 samples showing such symptoms were collected from the nearby areas of Thiruvallur  
206 district. The inhabitation of white-flies (*Bemisia tabaci*) on the leaves also ensured  
207 Begomovirus infection.

208

209 **Extraction of DNA from infected plant leaves**

210 Total Genomic DNA was extracted from the symptomatic squash leaf samples using  
211 protocol suggested by Dellaporta et al. in 1983. Two leaf discs from collected leaf  
212 samples were taken in a sterile eppendorf tube (1.5 ml) and ground with 700 µl of  
213 Dellaporta buffer using a micro pestle.<sup>58</sup> 100 µl of 10% SDS was added into the tube  
214 and mixed well and incubated at 65°C for 10 minutes using a water bath. This was  
215 followed by addition of 200 µl of 5 M potassium acetate and vortexing for 5 minutes.  
216 The sample tubes were then incubated in ice for 20 minutes. Afterwards, the tubes  
217 were centrifuged at 10,000 rpm for 15 minutes and supernatant was collected in a  
218 fresh eppendorf tube and equal volume of isopropanol was added, the tubes were then  
219 vortexed and incubated at -20°C for 30 minutes. After the incubation, the tubes were  
220 centrifuged at 10,000 rpm for 10 minutes and supernatant was discarded. To the  
221 remaining pellet, 70% ethanol was added and again centrifuged at 10,000 rpm for 15  
222 minutes. Supernatant was discarded and pellet was dried completely before addition  
223 of 50 µl distilled water and storage at -20°C.

224

225 **Confirmation of begomovirus infection using conventional techniques**

226 The infection in squash plants was confirmed using polymerase chain reaction (PCR)  
227 through selective amplification of coat protein gene. The primers specific to the *CP*  
228 gene of *Squash leaf curl China Virus* were used for the validation. The following

229 reactions mixture was prepared: 0.5µl nuclease free water, 5µl master mix, 0.25µl  
230 forward primer, 0.25µl reverse primer, 4µl extracted total DNA solution.

231

### 232 **Extraction of filtrate from squash plant leaves**

233 The plant leaf extract was prepared through filtration method. The symptomatic  
234 leaves (100 g) were washed in water and kept in -20°C overnight. The frozen leaves  
235 were then homogenized by 0.1 M Phosphate buffer using mortar and pestle. The plant  
236 extract was filtered through No.1 Whatmann filter paper.

237

### 238 **Immunopurification of virus particle using antibody-MNP conjugates**

239 The Ab-conjugated MNPs solution was taken in five tubes in equal volume. 25µl, 50  
240 µl, 75 µl, 100 µl and 125 µl of crude extract was added to the tubes followed by  
241 incubation at RT for 30 mins. Afterwards, coupling buffer at pH 7.0 was added and  
242 incubated for 1 h. The Ag-Ab-MNP complex was separated using a magnet and  
243 washed 3 times with washing buffer. This complex was later suspended in 200 µl of  
244 Antigen Retrieval buffer (ARB) at RT for 30 mins and kept under vortex.<sup>59</sup> The virus  
245 particle i.e. the antigen was purified from the debris.

246

### 247 **Results and discussion**


248 Iron oxide nanoparticles were prepared using a modified protocol of so far available  
249 co-precipitation method<sup>14,15</sup>. The Fe<sup>2+</sup> and Fe<sup>3+</sup> salts were co-precipitated using  
250 sodium hydroxide to form magnetite.

251

### 252 **In situ preparation of iron oxide nanoparticles modified with APTES**

253 Magnetite nanoparticles was synthesized using the modified co-precipitation method  
254 described previously. Fe(II) and Fe(III) salts were co-precipitated using the aqueous  
255 NaOH solution. The stoichiometric ratio of Fe<sup>3+</sup> to Fe<sup>2+</sup> was set to 2:1 in the solid  
256 phase at the pH range between 10 – 12 at 70°C. The reaction was carried out under the

257 continuous supply of Nitrogen gas. The co-precipitation method using  $\text{Fe}^{2+}$  and  $\text{Fe}^{3+}$   
 258 ions reacting in alkaline conditions has been extensively investigated and the  
 259 following reactions were proposed for the mechanism of magnetite formation:




264

265 Giving an overall reaction:



267 The reaction was carried out in Nitrogen atmosphere because magnetic nanoparticles  
 268 has the tendency to become maghemite<sup>60</sup> due to its instability and susceptibility to  
 269 oxygen. This can be represented by the following equation.



272 Thus prepared magnetite nanoparticles possess a net negative charge due to the  $-\text{OH}^-$   
 273 ions on their surface. The inter-particle distance therefore get decreased and tend to  
 274 come closer to each other causing aggregation of particles thus resulting in the  
 275 increase in the particle size.<sup>61,62,63,64,65</sup> The poly-dispersity among the particles makes  
 276 it unsuitable for bio-applications.<sup>66</sup> In order to overcome such problems, the surface of  
 277 iron oxide nanoparticles were coated with appropriate functional moiety. Certain  
 278 parameters were considered while choosing a suitable functional moiety: 1) the  
 279 stability of the surface coat, 2) type of biomolecule to be conjugated, 3) side chain  
 280 chemistry of the biomolecule, 4) dispersity of nanoparticles and 5) redox potential.  
 281 Upon functionalization with suitable capping agent, the nanoparticles stay apart from  
 282 each other due to the steric/electrostatic repulsion between particles. Here in, we  
 283 demonstrated the conjugation of anti-ACMV antibody on the surface of iron oxide  
 284 nanoparticles. Generally, antibody possess two ends: variable end and constant end.  
 285 The variable end inhabits most of the amino ( $-\text{NH}_3^+$ ) groups and the latter is known to  
 286 possess carboxyl groups. Therefore bio-conjugation was done using the  $-\text{COO}^-$  end  
 287 groups of the antibody which do not affect the specificity of the antibody. In order to  
 288 build a covalent linkage between the nanoparticles and antibody APTES was used as  
 289 coating compound. Upon encapsulation with APTES, the surface of the nanoparticles  
 290 were left positive. The following analyses were carried out for the physico-chemical

291 characterization of magnetic nanoparticles: Transmission electron microscopy,  
292 Particles size analyzer (DLS), Surface Charge Analysis (Zeta-sizer), X-ray diffraction  
293 (XRD), Fourier Transform Infrared Spectroscopy (FT-IR), Vibrating Sample  
294 Magnetometer (VSM) and UV-Visible Spectrophotometer.

295

## 296 **Characterization of APTES modified iron oxide nanoparticles**

### 297 **Particle size analyzer**

298 The size distribution of the magnetic nanoparticles was determined using Malvern  
299 Nano ZS Zetasizer. The size of the magnetic nanoparticles determined using the  
300 multiple scattering techniques through laser diffraction method was approximately  
301 from 10 to 100nm. The average diameter of the APTES-functionalized magnetic  
302 nanoparticles (APTES-MNPs) was ~25nm (Fig. 2a).

303 The particle size is the main factor that makes the particle suitable for various  
304 applications. Especially, the particles can be used for biomedical applications only at  
305 smaller size.<sup>67</sup> It has been known that the particle size of the particles depends on the  
306 acidity and the ionic strength of the medium.<sup>13,68</sup> The particle size decreases at higher  
307 pH and ionic strength. The chemical composition on the surface of the particles and  
308 consecutively, the surface charge of the particles are determined by the pH and the  
309 ionic strength of the medium. Another factor that influences the particle size is the  
310 mixing rate of the solution. As the mixing rate increases the size of the particles tend  
311 to decrease. The limit of oxidation rate is also factors influencing the particle size. It  
312 has been proved that bubbling of medium with nitrogen decreases the particle size  
313 when compared to the methods without oxygen removal.<sup>69,70</sup> The particle size is also  
314 dependent on the proportion of the iron salts used for the preparation of iron oxide  
315 nanoparticles.<sup>71</sup>

316

### 317 **Surface Charge Analysis**

318 The surface charge or the zeta potential ( $\zeta$ ) of the magnetic nanoparticles was  
319 analyzed in Malvern ZS Nano instrument using laser Doppler velocimetry technique.  
320 The APTES-MNPs exhibited positive charge of around +25mV at <pH 10 which is  
321 essential for an ideal electrostatic stabilization. The surface charge of the particles is  
322 positive due to the silane molecule APTES that has been coated on the surface of the

323 magnetic nanoparticles at neutral pH<sup>72</sup> indicating that all the -NH<sub>2</sub> groups have been  
324 transformed to -NH<sub>3</sub><sup>+</sup> group. The surface charge was determined by the pH of the  
325 solution. Since the silanization process was carried out in neutral pH, the zeta  
326 potential was taken at pH 6.8. The electrostatic repulsion between the particles is  
327 based on the surface charge of the particles. The net positive charge of the particles  
328 makes the particle repel each other. The repulsion force between particles has  
329 prevented them from aggregation maintaining mono-dispersity.<sup>21</sup> (Fig. 2b). Therefore,  
330 surface bio-functionalization of magnetic nanoparticles is a most important step to  
331 prepare stable particles in the medium. A net positive charge is most vital for the  
332 covalent immobilization of antibody on the magnetic nanoparticles. The result proves  
333 that the particles are stable in the medium at neutral pH.

334

### 335 **Fourier Transform Infra-red spectroscopy (FT-IR)**

336 The coating of the magnetite surface through silanization was confirmed using FTIR  
337 spectroscopy. Fig. 2c shows the FTIR spectra of the MNPs and APTES-MNPs. For  
338 MNPs nanoparticles, the characteristic absorption peaks at 601 and 702 cm<sup>-1</sup> are  
339 attributed to the Fe-O stretching in the (*a-b*) plane.<sup>73</sup> APTES is adsorbed on the  
340 magnetite nanoparticles surfaces by Fe-O-Si bond, because of the absorption band  
341 corresponded to this band appears at around 601 cm<sup>-1</sup> and therefore overlaps with the  
342 Fe-O bend, while Si-O stretching was observed at 987.48 cm<sup>-1</sup>.<sup>74</sup> The band at 1319.2  
343 and 1396.36 cm<sup>-1</sup> corresponds to C-O stretch and C-H bend, respectively. The IR  
344 absorbance at 1650.94 cm<sup>-1</sup> corresponds to the stretching vibration at N-H bend which  
345 is a primary amine, NH<sub>2</sub> groups, confirm the existence of APTES. Finally, the weak  
346 FTIR peak at 3618.1 cm<sup>-1</sup> relates to the free O-H groups concerned with surface  
347 exposed MNPs. Therefore, the presence of Fe-O bend, Si-O stretching, and N-H bend  
348 provide evidence for APTES being functionalized on the surface of MNPs.

349

### 350 **X-ray Diffraction Techniques**

351 The XRD data revealed typical X-ray powder diffraction patterns of magnetite  
352 nanoparticles at pH 7 (Fig. 2d). The structural and phase investigation of samples are  
353 analyzed by XRD measurements which have been compared with the standard data at  
354 the solution with pH 7. There are no significant existence of other phase or impurity.  
355 It was found that the samples showed crystalline and strong orientation at (220),  
356 (311), (400), (422), (511) and (440) planes with 2θ= 30.0°, 35.4°, 43.0°, 53.4°, 56.9°

357 and  $62.5^\circ$ , respectively. There are no intense peaks along (110), (210), (211) that are  
358 corresponding to  $\gamma\text{-Fe}_2\text{O}_3$  particles.<sup>68,75</sup> The crystalline grain size was determined  
359 using Debye-Scherrer Equation  $D = 0.9\lambda / (\beta \cos\theta)$  for intense peak. The calculated  
360 average size of the nanoparticles calculated from XRD studies is 14.05nm. The fact,  
361 based on the Ostwald ripening theory,<sup>76</sup> the precipitated particles possesses larger  
362 crystalline sizes due to the high pH and the increased temperature. After surface  
363 modification, the particles become smaller due to the inter-particle repulsion force.  
364 Comparatively, small particles are preferred for their higher surface energy.<sup>68</sup>

365

### 366 **Vibrating Sample Magnetometer**

367 The characterization of the magnetic properties of the  $\text{Fe}_3\text{O}_4$  nanoparticles was done  
368 using vibrating sample magnetometer (VSM) at room temperature thereby cycling the  
369 magnetic field between -15000 to +15000  $O_e$ , where parameters such as saturation  
370 magnetization ( $M_s$ ) and coercive field ( $H_c$ ) were evaluated. Hysteresis curves of the  
371 magnetic nanoparticles in powder state was measured (Fig. 2e). The nano-fluidic  
372 behavior of the magnetite nanoparticles was mainly determined by their magnetic  
373 properties. It has been known that in the existence of magnetic field  $H$ , the magnetic  
374 moment ( $\mu$ ) of the particles will tend to arrange along the magnetic field direction,  
375 leading to a macroscopic magnetization of the liquid. These type of magnetic  
376 materials show hysteresis loops (M-H curves) which could be defined by the  
377 irreversibility in the magnetization process related to the pinning of magnetic domain  
378 walls at impurities or crystal defects which often restricts the domain wall motion.  
379 Another potential cause of such a behavior is the magnetic anisotropy of the  
380 crystalline lattice. With the increase in the applied field, the domains change size and  
381 rotate until the materials gets fully magnetized leading to the saturation magnetization  
382 ( $M_s$ ). The magnetic moment of the particle freely oscillate with respect to the heat  
383 energy. Thus obtained saturation magnetization,  $M_s$  and coercive field,  $H_c$  at room  
384 temperature were 14.5 emu/g. It has been suggested that  $M_s$  of nearly 7-22 emu/g is  
385 found suitable for biomedical applications.<sup>77,78</sup> The decrease in the size of the  
386 magnetic nanoparticles results in the decrease of saturation magnetization which is  
387 due to the large deformations occurred on the surface of small particles. The mean  
388 magnetic diameter ( $D_{mag}$ ) and the standard deviation,  $\sigma$  calculated based on the low  
389 field and high field portions at room temperature using Chantrell's equation.<sup>68,79</sup> Thus  
390 synthesized APTES-MNPs found suitable for the application of virus purification.

391

392 **Bio-functionalization of antibody on magnetic nanoparticles**

393 In order to immobilize protein molecules, the side chain of protein of interest has to  
394 be activated with suitable linker and the nanoparticles as well. The purpose of surface  
395 activation of Fe<sub>3</sub>O<sub>4</sub> nanoparticles was solved by coating the nanoparticles with  
396 APTES to form self-assembled monolayers on the surface of these magnetic  
397 nanoparticles. The side chain carboxylic group of the antibody molecule was activated  
398 by EDC-NHS strategy.<sup>80</sup>

399 There are two methods so far to immobilize antibody on nanoparticle surface; Non-  
400 oriented binding and Oriented Binding. In non-oriented binding, the antibodies are  
401 directly immobilized on the surface of the magnetic nanoparticles, the most common  
402 method that applies ionic based interaction between the antibody and nanoparticle  
403 complex. This type of immobilizing antibodies on magnetic nanoparticles may disturb  
404 the coupling efficiency of antibody to the antigen either due to the steric restrictions  
405 or the blocking up of reactive sites that aids in the specificity of the molecule.  
406 Therefore, specificity of antibody can be increased only through 'targeted binding' or  
407 the 'oriented binding' approach achieved by the covalent immobilization of magnetic  
408 nanoparticles to the Fc domain in the antibody<sup>81</sup>.

409 The amount of antibody loaded on the surface of the magnetic nanoparticles were  
410 measured using Bradford assay. The calibration curve was obtained from the  
411 absorbance derived at 595nm (data not shown). The antibody concentration was  
412 measured in the sample tube before and after conjugation to magnetic nanoparticles.  
413 The amount/percentage of surface bound protein on the magnetite nanoparticles was  
414 calculated from the residual protein left out in the sample tube after bio-  
415 functionalization. The percentage of antibody loaded could be calculated using the  
416 following formula:

417

$$418 \quad \text{Percentage of Antibody (\%)} = \left( \frac{\text{Initial Concentration of Antibody} - \text{Final Concentration of antibody}}{\text{Initial Concentration of Antibody}} \right) \times 100$$

419

420

421 In such a way, it was found that nearly 75% of the antibody molecules were  
422 immobilized on 1 mg of magnetic nanoparticles, i.e. the given initial concentration of  
423 antibody was 1.2 mg/mL and the final quantity of antibody left in the sample tube was

424 0.35 mg/mL (Fig. 3b). The high percent of loading of antibody on the surface of the  
425 magnetic nanoparticles is due to the activation of the carboxyl group in the antibody  
426 at a slightly acidic pH.<sup>82</sup> Further the Ab-MNPs were characterized using particle size  
427 analyzer. The antibody-conjugated magnetic nanoparticles showed a drastic change in  
428 their size compared to bare MNPs which might be due to the surface capping of the  
429 nanoparticles by the antibody.

430 It is because of the polymeric nature of the antibody the magnetic nanoparticles come  
431 close together to increase the size of the particles. Thus measured size of the particles  
432 was ~80nm in diameter (Fig. 3a). This result clearly indicates that the hydrodynamic  
433 diameter of the particles has increased due to the agglomeration of particles caused by  
434 antibody.

435

#### 436 **Bio-Separation of Begomovirus using Ab-MNPs**

437 The Ab-MNPs were used to precipitate the virus particles from the solution. The  
438 antibody-conjugated magnetic nanoparticles aggregated due to the adhered virus and  
439 the formed hydrogen bonding in between the viral antigen and the antibody. The  
440 increase in the size of the magnetic nanoparticles were measured using the particle  
441 size analyzer (Fig. 4a).

442 The hydrodynamic diameter of the nanoparticles increased to nearly 1100 nm i.e. 1.1  
443  $\mu\text{m}$  which confirms the immunoprecipitation complex in between the magnetic  
444 nanoparticles. SDS PAGE analysis for the solution eluted from the first wash was run  
445 along with the partial purified sample (Fig. 4c). In gel lane 1, the separated crude  
446 extract sample has found to possess multiple protein bands. It is clearly understood  
447 that the appeared multiple protein bands was due to the presence of enormous plant  
448 proteins. This has been further proven by UV-Visible spectrophotometer (Fig. 4b),  
449 which exhibit peak at 265 nm indicating the presence of biomolecules, i.e.  
450 DNA/proteins. The amplification of CP gene in the crude extract indicates the  
451 presence of viral infection (control). But the CP gene was not amplified in MNPs  
452 treated samples (Fig. 4d). This clearly indicates that huge amount of virus particles  
453 have adhered to the antibody immobilized magnetic nanoparticles. During the second  
454 wash and the third wash, the virus particles were not found. The antigen-antibody-  
455 MNP aggregates were suspended to antigen retrieval buffer (ARB) at pH 10. The  
456 ionic strength of the solution plays an important role in the release of captured

457 antigen. It is also due to the fact that surface charge of the virion particles becomes  
458 zero at that particular pH. After incubation with ARB, the antigen was released from  
459 the Ab-MNPs complexes and left free in the medium. The remaining Ab-MNP  
460 conjugates were separated using the magnet. The release of antigen in the solution  
461 was confirmed using the SDS-PAGE electrophoresis, PCR and Agarose gel  
462 electrophoresis. The SDS-PAGE showed intact bands between 56 kDa and 101 kDa,  
463 at ~85 kDa which should be a trimer of the 28.6 kDa coat protein of begomovirus  
464 (Fig. 5a)<sup>83</sup>. The isolated viral particles were compared with the viral particles  
465 extracted using the conventional techniques and the Ab-MNPs recycled to isolate  
466 viral particles in a sample (Fig. 5b). Therefore, it confers that these Ab-MNPs can be  
467 reproduced rather than get wasted. The presence of proteins was further confirmed  
468 using UV-Visible spectrophotometer as the absorbance peak was found at ~270nm  
469 (Fig. 5c). The broad peak at 400nm decreased indicating the reduction in the Ab-MNP  
470 complex. The CP gene was amplified using polymerase chain reaction in all the  
471 samples confirming the presence of virus particles (Fig. 5d). The antibody conjugated  
472 magnetic nanoparticles was more helpful in the purification of virus particles skipping  
473 the most expensive ultra-centrifuge technique. This technique employing the use of  
474 magnetic nanoparticles would help the research community in the  
475 bioseparation/purification of virus particles using a magnet.

476

## 477 **Conclusions**

478 This work reports for the first time about the powerful application of antibody  
479 conjugated MNPs in the purification of begomovirus from the infected plant samples.  
480 The hydrophobically prepared magnetic nanoparticles were modified into hydrophilic  
481 particles using APTES mediated silanization. APTES modified MNPs showed a mean  
482 diameter of ~25nm. Thus synthesized APTES-MNPs was conjugated with the  
483 antibodies specific for Begomovirus. The antibody-conjugated MNPs was found to be  
484 ~80nm in diameter due to the surface coverage with antibodies. While Ab-MNPs  
485 were suspended in the crude extract of ash gourd leaf samples, the Ab-MNPs has  
486 acquired the viral antigens through immunoprecipitation reaction resulting in a drastic  
487 increase in diameter i.e. 1100nm which were then separated using a magnet. Finally,  
488 after treating with Antigen retrieval buffer at pH 10, the captured virion particles are  
489 released into the buffer solution. The results were confirmed using SDS-PAGE,

490 Polymerase Chain reaction and agarose gel electrophoresis. This technique will serve  
491 as a great tool for researchers to skip off the time-consuming ultra-centrifugation step  
492 for the separation of biomolecules.

493

494 **References**

- 495 (1). S. Chikazumi, S. Taketomi, M. Ukita, M. Mizukami, H. Miyajima, M. Setogawa,  
496 Y. Kurihara, Physics of magnetic fluids, *J. Magn. Magn. Mater.*, 1987, **65**, 245.
- 497 (2). Lu, A.-H., Schmidt, W., Matoussevitch, N., BPnnermann, H., Spliethoff, B.,  
498 Tesche, B., Bill, E., Kiefer, W., SchVth, F. (2004) Nanoengineering of a  
499 magnetically separable hydrogenation catalyst. *Angew. Chem. Int. Ed.* **43**, 4303.
- 500 (3). Tsang, S. C., Caps, V., Paraskevas, I., Chadwick, D., Thompsett, D. (2004)  
501 Magnetically Separable, Carbon-Supported Nanocatalysts for the Manufacture of  
502 Fine Chemicals. *Angew. Chem. Int. Ed.* **43**, 5645.
- 503 (4). Gupta, A. K., Gupta, M. (2005) Synthesis and surface engineering of iron oxide  
504 nanoparticles for biomedical applications. *Biomaterials* **26**, 3995.
- 505 (5). Li, Z., Wei, L., Gao, M.Y., Lei, H. (2005) One-Pot Reaction to Synthesize  
506 Biocompatible Magnetite Nanoparticles. *Adv. Mater.* **17**, 1001.
- 507 (6). Mornet, S., Vasseur, S., Grasset, F., Verveka, P., Goglio, G., Demourgues, A.,  
508 Portier, J., Pollert, E., Duguet, E. (2006) Magnetic nanoparticle design for medical  
509 applications. *Prog. Solid State Chem.* **34**, 237.
- 510 (7). Hyeon, T. (2003) Chemical synthesis of magnetic nanoparticles. *Chem. Commun.*  
511 927-934.
- 512 (8). Elliott, D.W., Zhang, W. -X. (2001) Field assessment of nanoscale bimetallic  
513 particles for groundwater treatment. *Environ. Sci. Technol.* **35**, 4922-4926.
- 514 (9). Takafuji, M., Ide, S., Ihara, H., Xu, Z. (2004) Preparation of Poly(1-  
515 vinylimidazole)-Grafted Magnetic Nanoparticles and Their Application for  
516 Removal of Metal Ions *Chem. Mater.* **16**, 1977.
- 517 (10). Cabrera, L., Gutierrez, S., Menendez, N., Morales, M.P., Herrasti, P. (2008)  
518 Magnetite nanoparticles: electrochemical synthesis and characterization.  
519 *Electrochim Acta.* **53**, 3436.
- 520 (11). Pascal, C., Pascal, J. L., Favier, F. (1999) Electrochemical synthesis for the control  
521 of  $\gamma$ -Fe<sub>2</sub>O<sub>3</sub> nanoparticle size. *Chem Mater.* **11**, 141-147.
- 522 (12). Bomati-Miguel, O., Mazeina, L., Navrotsky, A., Veintemillas-Verdaguer, S.  
523 (2008) Calorimetric Study of Maghemite Nanoparticles Synthesized by Laser-  
524 Induced Pyrolysis. *Chem. Mater.* **20**, 591-598.
- 525 (13). Wu, W., He, Q., Jiang, C. (2008) Magnetic Iron Oxide Nanoparticles: Synthesis  
526 and Surface Functionalization Strategies. *Nanoscale Res Lett.* **3**, 397-415.

- 527 (14). Babes, L., Denizot, B., Tanguy, G., Jeune, J.J.L., Jallet, P. (1999) Synthesis of Iron  
528 Oxide Nanoparticles Used as MRI Contrast Agents: A Parametric Study. *J. Colloid*  
529 *Interface Sci.* 212, 474–482.
- 530 (15). Laurent, S., Forge, D., Port, M., Roch, A., Robic, C., Elst, L.V., Muller, R.N.  
531 (2008) Magnetic Iron Oxide Nanoparticles: Synthesis, Stabilization, Vectorization,  
532 Physicochemical Characterizations, and Biological Applications. *Chem. Rev.* 108,  
533 2064–2110.
- 534 (16). Punties VF, Krishnan KM, Alivisatos AP. Colloidal nanocrystal shape and size  
535 control: the case of cobalt. *Science.* 2001;291(5511):2115–2117. doi:  
536 10.1126/science.1057553.
- 537 (17). Park J, Lee E, Hwang NM, Kang MS, Kim SC. et al. One-nanometer-scale size-  
538 controlled synthesis of monodisperse magnetic iron oxide nanoparticles. *Angew*  
539 *Chem Int Ed.* 2005;44(19):2872–2877. doi: 10.1002/anie.200461665.
- 540 (18). Nitin N, LaConte LEW, Zurkiya O, Hu X, Bao G. Functionalization and peptide-  
541 based delivery of magnetic nanoparticles as an intracellular MRI contrast agent. *J*  
542 *Biol Inorg Chem.* 2004;9(6):706–712.
- 543 (19). Lee SJ, Jeong JR, Shin SC, Kim JC, Chang YH. et al. Nanoparticles of magnetic  
544 ferric oxides encapsulated with poly(D,L lactide-co-glycolide) and their applications  
545 to magnetic resonance imaging contrast agent. *J Magn Magn Mater.* 2004;272-  
546 276:2432–2433.
- 547 (20). Akbarzadeh, A., Samiei, M., Davaran, S. Magnetic nanoparticles: preparation,  
548 physical properties, and applications in biomedicine. *Nanoscale Res. Lett.* 2012, 7,  
549 144.
- 550 (21). LaConte, L., Nitin, N., Bao, G. (2005) Magnetic nanoparticle probes. *NanoToday*  
551 32.
- 552 (22). Wu, W., Dey, D., Memis, O.G., Katsnelson, A., Mohseni, H. (2008) A Novel Self-  
553 aligned and Maskless Process for Formation of Highly Uniform Arrays of  
554 Nanoholes and Nanopillars. *Nanoscale Res. Lett.* 3, 123-127.
- 555 (23). Sahoo, Y., Pizem, H., Fried, T., Golodnitsky, D., Burstein, L., Sukenik, C.N.,  
556 Markovich, G. (2001) Alkyl phosphonate/phosphate coating on magnetite  
557 nanoparticles: A comparison with fatty acids. *Langmuir* 17, 7907–7911.
- 558 (24). Lee, H., Lee, E., Kim, D.K., Jang, N.K., Jeong, Y.Y., Jon, S. (2006) Antibiofouling  
559 polymer-coated superparamagnetic iron oxide nanoparticles as potential magnetic

- 560 resonance contrast agents for in vivo cancer imaging. *J. Am. Chem. Soc.* *128*,  
561 7383–7389.
- 562 (25). Xu, J., Sun, J., Wang, Y., Sheng, J., Wang, F., Sun, M. (2014) Application of Iron  
563 Magnetic Nanoparticles in Protein Immobilization. *Molecules* *19*, 11465-11486.
- 564 (26). Khot, V.M., Salunkhe, A.B., Phadatare, M.R., Pawar, S.H. (2012) Formation,  
565 microstructure and magnetic properties of nanocrystalline Mg-Fe<sub>2</sub>O<sub>4</sub>. *Materials*  
566 *Chemistry and Physics* *132*, 782-787.
- 567 (27). Katz, E., Willner, I. (2004) Nanobiotechnology: integrated nanoparticle-  
568 biomolecule hybrid systems: Synthesis, properties, and applications. *Angew. Chem.*  
569 *Int. Ed.* *43*, 6042–6108.
- 570 (28). Ferrari, M. (2005) Cancer nanotechnology: Opportunities and challenges. *Nature*  
571 *Rev. Cancer* *5*, 161–171.
- 572 (29). Arruebo, M., Valladares, M., Gonzalez-Fernandez, A. (2009) Antibody-  
573 Conjugated Nanoparticles for Biomedical Applications. *Journal of Nanomaterials*  
574 *2009*, 1–24.
- 575 (30). Yang, J., Lee, C-H., Park, J., Seo, S., Lim, E-K., Song, Y.J., Suh, J-S., Yoon, H-G.,  
576 Huh, Y-M., Haam, S. (2007) Antibody conjugated magnetic PLGA nanoparticles  
577 for diagnosis and treatment of breast cancer. *J. Mater. Chem.* *17*, 2695-2699.
- 578 (31). Schlenoff, P. (2009) Antibody-coated magnetic nanoparticles: Targeting and  
579 treating cancer. *Young Scientists Journal* *8*, 33-36.
- 580 (32). Bushida, K., Mohri, K., Katoh, T., Kobayashi, A. (1996) Amorphous Wire MI  
581 Micro Magnetic Sensor for Gradient Field Detection. *IEEE Trans. Magn.* *32*,  
582 4944-4946.
- 583 (33). Shinkai, M., Ohshima, A., Yanase, M., Uchiyama, T., Mohri, K., Wakabayashi, T.,  
584 Yoshida, J., Honda, H., Kobayashi, T. (1998) Development of Novel Magnetic  
585 Sensing for Brain Lesion Using Functional Magnetic Particles. *Kagaku Kogaku*  
586 *Ronbunshu* *24*, 174-178.
- 587 (34). Chan, D.C.F., Kirpotin, D.B., Bunn, P.A. (1993) Synthesis and evaluation of  
588 colloidal magnetic iron oxides for the site-specific radiofrequency-induced  
589 hyperthermia of cancer. *J. Magn. Magn. Mater.* *122*, 374-378.
- 590 (35). Roque, A. C. A., Lowe, C. R., Taipa, M. Â. (2004) Antibodies and Genetically  
591 Engineered Related Molecules: Production and Purification. *Biotechnol Progress*,  
592 *20*, 639–654.

- 593 (36). Birch, J.R., Racher, A.J. (2006) Antibody production. *Adv Drug Deliv Rev.* 58,  
594 671-85.
- 595 (37). Roque, A.C., Silva, C.S., Taipa, M.A. (2007) Affinity-based methodologies and  
596 ligands for antibody purification: advances and perspectives. *J Chromatogr A.*  
597 1160, 44-55.
- 598 (38). Berensmeier, S. (2007) Magnetic particles for the separation and purification of  
599 nucleic acids. *Appl. Micro. Biotech.* 73, 495-504.
- 600 (39). Safarik, I., Safarikova, M. (2004) Magnetic techniques for the isolation and  
601 purification of proteins and peptides. *Biomagn Res Technol.* 2, 7.
- 602 (40). Xu, H., Aguilar, Z.P., Yang, L., Kuang, M., Duan, H., Xiong, Y., Wei, H., Wang,  
603 A. (2011) Antibody Conjugated Magnetic Iron Oxide Nanoparticles for Cancer  
604 Cell Separation in Fresh Whole Blood. *Biomaterials.* 32, 9758–9765.
- 605 (41). Sung, Y.J., Suk, H-J., Sung, H.Y., Li, T., Poo, H., Kim, M-G. (2013) Novel  
606 antibody/gold nanoparticle/magnetic nanoparticle nanocomposites for  
607 immunomagnetic separation and rapid colorimetric detection of *Staphylococcus*  
608 *aureus* in milk. *Biosens. Bioelectron.* 43, 432–439.
- 609 (42). Cui, Y. R., Hong, C., Zhou, Y-L., Li, Y., Gao, X-M., Zhang, X-X. (2011)  
610 Synthesis of orientedly bioconjugated core/shell Fe<sub>3</sub>O<sub>4</sub>@Au magnetic  
611 nanoparticles for cell separation. *Talanta* 85, 1246–1252.
- 612 (43). Chen, S., Yuan, Y., Yao, J., Hana, S., Gu, R. (2011) Magnetic separation and  
613 immunoassay of multi-antigen based on surface enhanced Raman spectroscopy.  
614 *Chem. Commun.* 47, 4225-4227.
- 615 (44). Böttcher, B., Unseld, S., Ceulemans, H., Russell, R.B., Jeske, H. (2004) Geminate  
616 structures of *African cassava mosaic virus*. *J Virol.* 78, 6758-65.
- 617 (45). Krupovic, M., Ravantti, J.J., Bamford, D,H. (2009) Geminiviruses: a tale of a  
618 plasmid becoming a virus. *BMC Evolutionary Biology* 9, 112.
- 619 (46). Zhang, S.C., Wege, C., Jeske, H. (2001) Movement proteins (BC1 and BV1) of  
620 Abutilon mosaic geminivirus are cotransported in and between cells of sink but not  
621 of source leaves as detected by green fluorescent protein tagging. *Virology.* 290,  
622 249-260.
- 623 (47). Swanson, M.M., Valand, G.B., Muniyappa, V., Harrison, B.D. (1998) Serological  
624 detection and antigenic variation of two whitefly-transmitted geminiviruses:  
625 tobacco leaf curl and croton yellow vein mosaic viruses. *Annals of Applied*  
626 *Biology*, 132, 427–435.

- 627 (48). Mohammed Riyaz, S.U., Deepan, S., Dharanivasan, G., Jesse, M.I. Raja  
628 Muthuramalingam, T., Kathiravan, K. (2013) First report on a variant of Squash  
629 leaf curl China virus (SLCCNV) infecting *Benincasa hispida* in India. *New Disease*  
630 *Reports* 28, 20.
- 631 (49). Czosnek, H., Ber, R., Antignus, Y., Cohen, S., Navot, N., Zamir, D. (1988)  
632 Isolation of Tomato Yellow Leaf Curl Virus, a Geminivirus. *Phytopathology*. 78,  
633 508-512.
- 634 (50). Vayssieres, L., Chaneac, C., Tronc, E., Jolivet, J.P. (1998) Size tailoring of  
635 magnetite particles formed by aqueous precipitation: An example of  
636 thermodynamic stability of nanometric oxide particles. *J. Colloid Interf. Sci.* 205,  
637 205-212.
- 638 (51). Hu, B., Pan, J., Yu, H.L., Liu, J.W., Xu, J.H. (2009) Immobilization of *Serratia*  
639 *marcescens* lipase onto amino-functionalized magnetic nanoparticles for repeated  
640 use in enzymatic synthesis of Diltiazem intermediate. *Proc. Biochem*, 44, 1019–  
641 1020.
- 642 (52). Mizukoshi, Y., Shuto, T., Masahashi, N., Tanabe, S. (2009) Preparation of  
643 superparamagnetic magnetite nanoparticles by reverse precipitation method:  
644 contribution of sonochemically generated oxidants. *Ultrason. Sonochem.* 16, 525–  
645 531.
- 646 (53). Nedkova, I., Merodiiskaa, T., Slavova, L., Vandenbergheb, R.E., Kusanoc, Y.,  
647 Takadad, J. (2006) Surface oxidation, size and shape of nano-sized magnetite  
648 obtained by co-precipitation. *J. Magn. Magn. Mater.* 300, 358–367.
- 649 (54). Qu, S., Yang, H., Ren, D., Kan, S., Zou, G., Li, D., Li, M. (1999). Magnetite  
650 nanoparticles prepared by precipitation from partially reduced ferric chloride  
651 aqueous solutions. *J. Colloid Interface. Sci.* 215, 190-192.
- 652 (55). Pardoe, H., Chua-anusorn, W., Pierre, T.G., Dobson, J. (2001) Structural and  
653 magnetic properties of nanoscale magnetic particles synthesised by coprecipitation  
654 of iron oxide in the presence of dextran or polyvinyl alcohol. *J. Magn. Mat.* 225,  
655 41–46.
- 656 (56). Bandhu, A., Mukherjee, S., Acharya, S., Modak, S., Brahma, S.K., Das, D.,  
657 Chakrabarti, P.K. (2009) Dynamic magnetic behavior and Mössbauer effect  
658 measurements of magnetite nanoparticles prepared by a new technique in the co-  
659 precipitation method. *Solid State Commun.* 149, 1790–1794.

- 660 (57). Ozkayaa, T., Toprakb, M.S., Baykala, A., Kavasc, H., Koseogluc, Y., Aktas, B.  
661 (2009) Synthesis of Fe<sub>3</sub>O<sub>4</sub> nanoparticles at 100°C and its magnetic  
662 characterization. *J. Alloys Compd.* 472, 18–23.
- 663 (58). Dellaporta, S.L., Wood, J., Hicks, J.B. (1983) A plant DNA Minipreparation  
664 version 2. *Plant Mol. Bio. Rep.* 1, 19-22.
- 665 (59). Shi, S.R., Imam, S.A., Young, L., Cote, R.J., Taylor, C.R. (1995) Antigen retrieval  
666 immunohistochemistry under the influence of pH using monoclonal antibodies. *J*  
667 *Histochem Cytochem.* 43, 193-201.
- 668 (60). Scholten, P.C., Feliuss, J.A.P. (1990) The magnetical and rheological behavior of  
669 aggregating magnetic suspensions. *J. Magn. Magn. Mater.* 85, 107–113.
- 670 (61). Cuyper, M.D., Joniau, M. (1991) Mechanistic aspects of the adsorption of  
671 phospholipids onto lauric acid stabilized magnetite nanocolloids. *Langmuir*, 7,  
672 647–652.
- 673 (62). Wooding, A., Kilner, M., Labrick, B.D. (1992) Stripped magnetic particles.  
674 Applications of the double surfactant layer principle in the preparation of water-  
675 based magnetic fluids. *J Colloid Interface Sci* 149, 98–104.
- 676 (63). Carpenter, E.E., O'Connor, C.J., Harris, V.G. (1999) Atomic structure and  
677 magnetic properties of MnFe<sub>2</sub>O<sub>4</sub> nanoparticles produced by reverse micelle  
678 synthesis. *J. Appl. Phys.* 85, 5175–5177.
- 679 (64). Sousa, M.H., Rubim, J.C., Sobrinho, P.G., Tourinho, F.A. (2001) Biocompatible  
680 magnetic fluid precursors based on aspartic and glutamic acid modified maghemite  
681 nanostructures. *J. Magn. Magn. Mat.* 225, 67–72.
- 682 (65). Canfarotta, F., Piletsky, S.A. (2014) Engineered Magnetic Nanoparticles for  
683 Biomedical Applications. *Advanced Healthcare Materials.* 3, 160–175.
- 684 (66). Vereda, F., Vicente, J., Hidalgo-Alvarez, R. (2007) Influence of a magnetic field in  
685 the formation of magnetite particles via two precipitation methods. *Langmuir* 23,  
686 3581–3589.
- 687 (67). Wang, B., Wei, Q., Qu, S. (2013) Synthesis and Characterization of Uniform and  
688 Crystalline Magnetite Nanoparticles via Oxidation-precipitation and Modified co-  
689 precipitation Methods. *Int. J. Electrochem. Sci.*, 8, 3786 – 3793.
- 690 (68). Xu, Z.Z., Wang, C.C., Yang, W.L., Deng, Y.H. (2004) Encapsulation of nanosized  
691 magnetic iron oxide by polyacrylamide via inverse miniemulsion polymerization. *J*  
692 *Magn. Magn. Mater.* 277, 136-143.

- 693 (69). Song, H-T., Choi, J-N., Huh, Y-M., Kim, S., Jun, Y-W., Suh, J-S., Cheon, J.  
694 (2005) Surface modulation of magnetic nanocrystals in the development of highly  
695 efficient magnetic resonance probes for intracellular labeling. *J. Am. Chem. Soc.*  
696 *127*, 9992-9993.
- 697 (70). Huh, Y-M., Jun, Y-W., Song, H-T., Kim, S., Choi, J-S., Lee, J-H., Yoon, S., Kim,  
698 K-S., Shin, J-S., Suh, J-S., Cheon, J. (2005) In Vivo Magnetic Resonance  
699 Detection of Cancer by Using Multifunctional Magnetic Nanocrystals. *J. Am.*  
700 *Chem. Soc. 127*, 12387–12391.
- 701 (71). Zakri, R.H., Zakri, R., Zakri, S., Hassan, K.U. (2011) Nanotechnology in Surgery:  
702 Tiny Solutions for Titanic Problems. *Ann. Pak. Inst. Med. Sci.* *7*, 37-41.
- 703 (72). Taira, S., Kaneko, D., Onuma, K., Miyazato, A., Hiroki, T., Kawamura-Konishi,  
704 Y., Ichiyanagi, Y. (2012) Synthesis and Characterization of Functionalized  
705 Magnetic Nanoparticles for the Detection of Pesticide International *J. Inorg. Chem.*  
706 *2012*.
- 707 (73). Cambier, P. Infrared study of goethites of varying crystallinity and particle Size: I.  
708 Interpretation of OH and Lattice vibration frequencies. *Clay Minerals*, 1986, **21**,  
709 191-200.
- 710 (74). Lerot, L., Low, P.F. (1976) Effect of swelling on the infrared absorption spectrum  
711 of montmorillonite. *Clays Clay Miner.* *24*, 191-199.
- 712 (75). Godbole, B., Badera, N., Shrivastava, S.B., Jain, D., Chandra, L.S.S., Ganesan, V.  
713 (2013) Synthesis, Structural, Electrical and Magnetic Studies of Ni- Ferrite  
714 Nanoparticles. *Physics Procedia* *49*, 2013, 58–66.
- 715 (76). Madras, G., McCoy, B.J. (2003) Continuous distribution theory for Ostwald  
716 ripening: comparison with the LSW approach. *Chem. Engg. Sci.* *58*, 2903 – 2909.
- 717 (77). Brusentsov, N.A., Gogosov, V.V., Brusentsova, T.N., Sergeev, A.V., Jurchenko,  
718 N.Y., Kuznetsov, A.A., Kuznetsov, O.A., Shumakov, L.I. (2001) Evaluation of  
719 ferromagnetic fluids and suspensions for the site-specific radiofrequency-induced  
720 hyperthermia of MX11 sarcoma cells in vitro. *J. Magn. Magn. Mater.* *225*, 113-  
721 117.
- 722 (78). Xu, C., Xu, K., Gu, H. Zhong, X, Guo, Z., Zheng, R., Zhang, X., Xu, B.  
723 (2004) Nitrilotriacetic acid-modified magnetic nanoparticles as a general  
724 agent to bind histidine-tagged proteins. *J. Am. Chem. Soc.* *126*, 3392–3393.

- 725 (79). Chantrell, R.W., Popplewell, J., Charles, S.W. (1978) Measurements of particle  
726 size distribution parameters in ferrofluids. *IEEE Trans. Magn.* 14, 975.
- 727 (80). Grabarek, Z., Gergely, J. (1990) Zero-Length Crosslinking Procedure with the Use  
728 of Active Esters. *Anal. Biochem.* 185, 131.
- 729 (81). Lin, P-C., Chen, S-H., Wang, K-Y., Chen, M-L., Adak, A-K., Hwu, J-R.R., Chen,  
730 Y-J., Lin, C-C. (2009) Fabrication of Oriented Antibody-Conjugated Magnetic  
731 Nanoprobes and Their Immunoaffinity Application. *Anal. Chem.* 81, 8774–8782.
- 732 (82). Packer, L., Tristram, S., Herz, J.M., Russel, C., Borders, L.C. (1979) Chemical  
733 modification of purple membranes: role of arginine and carboxylic acid residues in  
734 bacteriorhodopsin. *FEBS. Lett.* 108, 243–248.
- 735 (83). Zhou, Y., Rojas, M.R., Park, M-R., Seo, Y-S., Lucas, W. J., Gilbertson, R.L.  
736 (2011) Histone H3 Interacts and Colocalizes with the Nuclear Shuttle Protein and  
737 the Movement Protein of a Geminivirus. *Journal of Virology*, 85, 11821–11832.  
738


739 Fig. 1. Schematic representation of the methodology of eluting virion particles using  
740 Ab-MNPs.

741 Fig. 2. a) Particle size analysis data showing that the hydrodynamic diameter of  
742 APTES-MNPs at ~25 nm. Inset: Scheme of APTES-MNPs; b)  $\zeta$ -potential analysis  
743 showing the peak at +24.4mV, a net positive charge; c) FT-IR analysis showing peak  
744 for A) Bare MNPs, B) APTES-MNPs corresponding to Fe-O stretch, Si-O bend and  
745 N-H bend; d) XRD data showing peaks of bare MNPs compared with APTES-MNPs  
746 at (220), (311), (400), (422), (511), (440). e) Hysteresis loop obtained from VSM  
747 measurements of synthesized MNPs functionalized with APTES at Room  
748 temperature.


749 Fig. 3. a)  $\zeta$ -potential analysis data showing increase in the size of the nanoparticles  
750 after the immobilization of antibody on magnetic nanoparticles; b) UV-visible  
751 spectrophotometer analysis of residual antibody concentration after binding to  
752 APTES-MNPs showing reduction in the amount of protein.

753 Fig. 4.  $\zeta$ -potential analysis data showing increase in the hydrodynamic diameter of  
754 the Ab-MNPs upon addition of virion particles; b) UV-Visible spectrophotometer  
755 analysis showing absorbance at ~260nm indicative of unbound protein molecule  
756 (impurities); c) SDS-PAGE analysis showing unbound protein (impurities) bands. M-  
757 Broad range protein marker, 1 – crude extract from plants, 2-6 showing eluted impure  
758 proteins at concentrations 25 $\mu$ L, 50 $\mu$ L, 75 $\mu$ L, 100 $\mu$ L, 125 $\mu$ L respectively; d)  
759 Fluorogram of amplification of *CP* gene from the unbound protein molecules showing  
760 no amplification in other samples indicative of absence of virion particles in the elute.


761 Fig. 5. a) SDS-PAGE analysis of virion particles eluted using the antibody-conjugated  
762 MNPs showing protein bands at ~85kDa; b) UV-visible spectrophotometer analysis  
763 showing elevated peak at ~260nm indicating the presence of protein molecules after  
764 elution using Ab-MNPs; c) Fluorogram of amplification of *CP* gene from the finally  
765 eluted sample showing bands at 500bp indicating the presence of virion particles in  
766 the elution done using Ab-MNPs.




188x308mm (300 x 300 DPI)



269x139mm (300 x 300 DPI)



120x178mm (300 x 300 DPI)



112x102mm (200 x 200 DPI)

